KFG Wealth Management LLC Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

KFG Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 14.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,821 shares of the company’s stock after buying an additional 626 shares during the quarter. KFG Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $415,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NVO. Raymond James & Associates lifted its position in Novo Nordisk A/S by 1.0% in the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after acquiring an additional 36,223 shares during the last quarter. Natixis Advisors LLC increased its position in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. LPL Financial LLC boosted its position in shares of Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after purchasing an additional 47,496 shares during the period. Finally, Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $98,765,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $87.94 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market cap of $394.65 billion, a price-to-earnings ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The firm’s fifty day moving average price is $95.35 and its 200 day moving average price is $115.17. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.